Trial Profile
A study to evaluate the clinical outcomes of single nucleotide polymorphisms on pharmacokinetic genes in japanese patients with metastatic renal cell carcinoma.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Jun 2017
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Biomarker; Pharmacokinetics; Therapeutic Use
- 16 May 2017 Results (n=26) assessing associations between the pharmacokinetics of sunitinib and its metabolite N-desethyl-sunitinib and adverse events (AEs) and clinical outcomes, presented at the 112th Annual Meeting of the American Urological Association
- 16 May 2017 Results (n=25) assessing effect of genetic polymorphism on the pharmacokinetics of Sunitinib, presented at the 112th Annual Meeting of the American Urological Association
- 19 Aug 2015 New trial record